Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

University of Toronto

$17,500.00

Randomized, Double-Blinded, Placebo-Controlled Study Evaluating Vortioxetine for Cognitive Deficits in Persons with Post-COVID-19 Condition

EF 2021-22

Résumé
Since the declaration of the COVID-19 pandemic by the World Health Organization, over 259 million people have tested positive for COVID-19. A notable percentage of individuals who were previously infected with COVID-19 continue to experience persisting and functionally impairing symptoms, which have collectively been identified as ;post COVID-19 condition. Anhedonia (inability to experience pleasure) and impaired reward function (inability to experience reward) are common symptoms of post COVID-19 condition, which also have a negative impact on quality of life.Currently, no treatment options exist to treat the foregoing symptoms of post COVID-19 condition. As such, my project aims to evaluate the effectiveness of vortioxetine, a Health Canada-approved antidepressant, in treating anhedonia and reward function among persons with post COVID-19 condition. In this 8-week randomized, double-blinded, placebo-controlled clinical trial, participants will receive 10-20mg of the study medication (i.e., placebo or vortioxetine). Clinical assessments and questionnaires will be administered, and changes in those outcomes will be analyzed. Results from this study may increase treatment options for post COVID-19, as well as further our knowledge about COVID-19 and its long-term impacts on human health and health systems.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
467059
Name
Lui Leanna
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Randomized, Double-Blinded, Placebo-Controlled Study Evaluating Vortioxetine for Cognitive Deficits in Persons with Post-COVID-19 Condition
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Anhedonia; Antidepressant; Cognition; Covid-19; Function; Post Covid-19 Condition; Quality Of Life; Reward; Wellbeing
Abstract
Since the declaration of the COVID-19 pandemic by the World Health Organization, over 259 million people have tested positive for COVID-19. A notable percentage of individuals who were previously infected with COVID-19 continue to experience persisting and functionally impairing symptoms, which have collectively been identified as ;post COVID-19 condition. Anhedonia (inability to experience pleasure) and impaired reward function (inability to experience reward) are common symptoms of post COVID-19 condition, which also have a negative impact on quality of life.Currently, no treatment options exist to treat the foregoing symptoms of post COVID-19 condition. As such, my project aims to evaluate the effectiveness of vortioxetine, a Health Canada-approved antidepressant, in treating anhedonia and reward function among persons with post COVID-19 condition. In this 8-week randomized, double-blinded, placebo-controlled clinical trial, participants will receive 10-20mg of the study medication (i.e., placebo or vortioxetine). Clinical assessments and questionnaires will be administered, and changes in those outcomes will be analyzed. Results from this study may increase treatment options for post COVID-19, as well as further our knowledge about COVID-19 and its long-term impacts on human health and health systems.
Competitiondate
202112
Approvedterm2
1 yr 0 mth
Pinamesdelim
Lui, Leanna
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~